UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1011-12
Program Prior Authorization/Notification
Medication Berinert® (C1 esterase inhibitor, human)
P&T Approval Date 11/2012, 11/2013, 8/2014, 8/2015, 7/2016, 7/2017, 7/2018, 7/2019,
7/2020, 7/2021, 7/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Berinert is a plasma-derived C1 esterase inhibitor (human) indicated for the treatment of acute
abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and pediatric
patients. The safety and efficacy of Berinert for prophylactic therapy has not been established.1
2. Coverage Criteriaa:
A. Berinert will be approved based on all of the following criteria:
1. Diagnosis of hereditary angioedema (HAE)
-AND-
2. For the treatment of acute HAE attacks
-AND-
3. Not used in combination with other products indicated for acute HAE attacks (e.g.,
Firazyr, Kalbitor or Ruconest)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
© 2024 UnitedHealthcare Services, Inc.
1
3. References:
1. Berinert [package insert]. Kankakee, IL: CSL Behring LLC; September 2021.
Program Prior Authorization/Notification - Berinert® (C1 esterase inhibitor,
human)
Change Control
11/2013 Annual review. Removed requirement for Type I or II HAE. Changed
authorization duration from 12 months to 60 months.
8/2014 Annual review. Added an additional criterion that does not allow
combination use with other HAE acute treatments. Decreased
authorization from 60 months to 12 months. Updated Background and
References.
8/2015 Annual Review. Updated references.
7/2016 Annual Review with no changes to the coverage criteria. Updated
background and references.
7/2017 Annual review with no changes to the coverage criteria. Updated
background and references.
7/2018 Annual review with no changes to the coverage criteria. Updated
references.
7/2019 Annual review with no changes to coverage criteria. Updated
references.
7/2020 Annual review with no changes to coverage criteria.
7/2021 Annual review with no changes to coverage criteria. Updated
references.
7/2022 Annual review with no changes to coverage criteria. Added state
mandate footnote. Updated reference.
7/2023 Annual review. Revised wording of criteria without change to clinical
intent.
7/2024 Annual review with no changes to coverage criteria.
© 2024 UnitedHealthcare Services, Inc.
2